LASERVISION/VISX EXCIMER LASER MODEL C

FDA Premarket Approval P960019

This medical device has supplements. The device description/function or indication may have changed. Be sure to look at the supplements to get an up-to-date information on device changes. The labeling included below is the version at time of approval of the original pma or panel track supplement and may not represent the most recent labeling.

Pre-market Approval Supplement Details

Device indicated for: 1)ptk in patients w/decreased best corrected visual acuity and/or with disabling pain that are the result of superficial corneal epithelial irregularities or stromal scars in the anterior one-third of the cornea. The patients must have failed w/alternative treatment options. For safety, the immediate postoperative corneal thickness must not be less than 250 microns. Examples of those conditions that warrant ptk are: a)corneal scars & opacity (from trauma and inactive infections), b)dystrophies (reis-buckler's, granular and lattice), c)thygeson's superficial keratitis, d) irregular corneal surfaces associated w/filamentary keratitis and salzmann's nodular degeneration, e)residual band keratopathy after unsuccessful edta treatment, and, f)scars subsequent to previous (not concurrent) pterygium excision. 2)prk for a 6. 0 ablation zone in patients who are myopic and meet all of the following criteria: 1)1. 0 to 6. 0 diopters (d) of myopia with astigmatism of 2. 0 diopters; b)refractive change is within 0. 5d for one year prior to the laser treatment; and c)18 years of age or older.

DeviceLASERVISION/VISX EXCIMER LASER MODEL C
Generic NameExcimer Laser System
ApplicantLASER VISION CENTERS, INC.
Date Received1996-06-03
Decision Date1996-11-15
Notice Date1997-07-23
PMAP960019
SupplementS
Product CodeLZS 
Docket Number97M-0256
Advisory CommitteeOphthalmic
Expedited ReviewNo
Combination Product No
Applicant Address LASER VISION CENTERS, INC. 540 Maryville Centre Dr., #200 st. Louis, MO 63141

Supplemental Filings

Supplement NumberDateSupplement Type
P960019Original Filing
S002 1998-04-17 Real-time Process
S001 1996-11-22 Normal 180 Day Track

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.